Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Gastric Adenocarcinoma|Esophageal Cancer|Hepatocellular Carcinoma|Non-small Cell Lung Cancer|Small Cell Lung Cancer|Ovarian Epithelial Cancer|Carcinoma Breast Stage IV|Hormone-refractory Prostate Cancer|Head and Neck Cancers- Squamous Cell|Renal Cell Cancer|Urinary Bladder Neoplasms|Cervical Cancer|Endometrial Cancer|Glioblastoma Multiforme|Triple Negative Breast Cancer|Pancreatic Cancer
Interventions: DRUG: Sacituzumab Govitecan-hziy (SG)
Sponsor: Gilead Sciences